Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication ...
In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR ...
Bio-Rad (CA, USA), a clinical diagnostics products company, has launched a new ddPCR kit designed to assess AAV vector quality for gene therapy development. Vericheck ddPCR Empty-Full Capsid Kit can ...
Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility of our teams in what ...
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results